FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Paul G. Kluetz, Laleh Amiri‐Kordestani et al.|Clinical Cancer Research|2022Cited by 236
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated TumorsJaleh Fallah, Julia A. Beaver, Michael H. Brave et al.|Clinical Cancer Research|2022Cited by 180
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval SummaryPaul G. Kluetz, Richard Pazdur, William F. Pierce et al.|Clinical Cancer Research|2013Cited by 171
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Richard Pazdur, Lynn Howie et al.|Clinical Cancer Research|2018Cited by 133
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Richard Pazdur, Erik Bloomquist et al.|Clinical Cancer Research|2018Cited by 115